Phase 3 N=1,008 Reevaluation Of Systemic Early Neuromuscular Blockade
Acute Respiratory Distress Syndrome
Primary: Hospital Mortality to Day 90 — 288; 289; 213; 216 Participants — p=0.93
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=71 Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression Free Survival (PFS) — 4.731; 0.986 months
Phase 2 N=40 Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
Dermatitis, Atopic
Primary: Change From Baseline in Lesion Total Sign Score (TSS) for Target Lesions Treated With Crisaborole Ointment 2% or Vehicle at Day 15 — -4.5; -2.1 units on a scale…
Phase 4 N=34 Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs
Hepatitis C
Primary: sCD14 (ng/mL) — 1986; 1918; 1542; 2060 ng/mL — p=0.07
Phase 2 N=39 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
Neuroblastoma
Primary: Assess the Impact of High-dose 3F8/GM-CSF
Phase 3 N=572 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Breast Cancer
Primary: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort — 11.0; 5.7 Months — p=0.00065
N/A N=255 Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness
Schizophrenia · Bipolar Disorder
Primary: Score on the Brief Psychiatric Rating Scale (BPRS) — 43.2; 41.6; 42.0; 41.0 units on a scale
N/A N=89 Paracervical Versus Intracervical Lidocaine
Abortion, Induced · Pain
Primary: Pain Score, as Assessed Using a 10 cm Linear Visual Analog Scale (VAS) — 4.25; 3.97 units on a scale
Phase 2 N=14 Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate — 6; 7 Participants
N/A N=69 Clinical Outcomes of Deep Brain Stimulator (DBS) Electrodes Placed Using Intraoperative Computed Tomography (CT) and Frameless Stereotaxis
Parkinson's Disease
Primary: Change in Motor OFF Ldopa UPDRS — 14.8 motor UPDRS
Phase 4 N=172 Opioid Analgesia for MAB
MAB · Pain
Primary: Overall Maximum Self-reported Pain Score — 8; 8 units on a scale
Phase 2 N=17 Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?
Smoking
Primary: Latency — 24.56; 26.64 minutes
Phase 2 N=14 Effect of Intranasal Insulin on LH Concentrations in Man
Hypogonadotropic Hypogonadism
Primary: LH — 7.7; 3.3; 7.9; 3.8 IU/L
Phase 2 N=25 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
KIF5B-RET-Positive Adenocarcinoma of the Lung
Primary: Objective Response Rate (ORR) — 16.0 percentage of participants
Phase 3 N=57 Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Choriocarcinoma · FIGO Stage I Gestational Trophoblastic Tumor · FIGO Stage II Gestational Trophoblastic Tumor
Primary: Percentage of Participants With Complete Response — 78.6; 88.5 percentage of participants